TrialA Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Trial details
- Registry ID
- NCT06246110
- Phase
- Phase 2
Drug research
EIK1001
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110 | Eikon Therapeutics | Phase 2 | Active not recruiting | 2026-12Estimated |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.NCT06697301 | Eikon Therapeutics | Phase 2, Phase 3 | Recruiting | 2035-12Estimated |
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319 | Eikon Therapeutics | Phase 2, Phase 3 | Recruiting | 2035-12-31Estimated |
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Trial details
- Registry ID
- NCT06697301
- Phase
- Phase 2, Phase 3
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Trial details
- Registry ID
- NCT07365319
- Phase
- Phase 2, Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |